Alzprotect

Executive Summary

Alzprotect is a French biopharmaceutical company founded in 2007, dedicated to developing small molecule therapies for neurodegenerative diseases, with a focus on tauopathies such as Progressive Supranuclear Palsy (PSP) and Alzheimer's disease. Its lead asset, AZP2006, employs a novel multi-target mechanism of action designed to halt neurodegeneration and restore brain function. Currently in Phase 2 clinical trials, AZP2006 targets tau protein aggregation and associated neuroinflammation, addressing key pathological hallmarks. The company's pipeline, while early-stage, holds promise for diseases with high unmet need and limited treatment options.

Upcoming Catalysts (preview)

• H1 2027Phase 2 interim data for AZP2006 in PSP45% success
• Q4 2026Regulatory feedback for Phase 3 design in Alzheimer's50% success
• TBDPotential partnership or licensing deal for AZP200630% success